# US 12,214,090 B2 · Kind of wound dressing for haemostasis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,214,090 B2 - Document ID: US12214090B2 - Status: Granted - Kind: B2 - Application number: 16/631,184 - Filed: 2018-07-20 - Published: 2020-07-09 - Granted: 2025-02-04 - Earliest claimed: 2017-07-21 - Assignees: Speed Care Mineral GmbH - Applicants: Speed Care Mineral GmbH - Inventors: Joachim Schomburg; Marta Loffler; Christian Schultz; Eckhard Salzsieder; Wolfgang Frohn - Web page: https://patentgrep.com/patent/US12214090B2 ## CPC - A61L 15/18: containing inorganic materials - A61L 15/40: containing ingredients of undetermined constitution or reaction products thereof {, e.g. plant or animal extracts} - A61L 15/42: Use of materials characterised by their function or physical properties (liquid bandages A61L26/00) - A61L 15/44: Medicaments - A61L 2300/102: Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates - A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents - A61L 2300/418: Agents promoting blood coagulation, blood-clotting agents, embolising agents - A61L 2400/04: Materials for stopping bleeding - A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) ## Abstract A wound dressing is which has haemostatic, coagulation-promoting and biocidal properties and can therefore be utilized particularly for acute wound care. Typical areas of application for acute wound care are, for example, the treatment of gunshot wounds. The wound dressing features selected halloysites which, for example, are applied to textile fibers or non-woven materials. ## Claims ### Claim 1 A haemostatic wound dressing, wherein the haemostatic wound dressing has a textile substrate having a first surface and an opposing second surface, the textile substrate being a non-woven fabric, a woven material, a gauze, a knitted fabric, a crotched fabric, or a scrim; and comprises halloysite patterned layer only on portions of the first surface by silk screening; wherein the haemostatic wound dressing does not contain calcium-ion additives, wherein the halloysite is applied on the first surface of the textile substrate as a layer, the opposing surface being uncoated by additional halloysite content, wherein the textile substrate has a density between 30 g/m2 and 120 g/m2, and wherein the halloysite has been pretreated to convert Halloysite-10 Å to Halloysite-7 Å. ### Claim 2 (depends on 1) The haemostatic wound dressing according to claim 1, wherein the textile substrate further comprises composite fibres. ### Claim 3 (depends on 2) The haemostatic wound dressing according to claim 2, wherein the composite fibres comprise a mixture, and components of the mixture are selected from the group consisting of viscose, algae, milk protein fibres, and combinations thereof. ### Claim 4 (depends on 2) The haemostatic wound dressing according to claim 2, wherein the composite fibres are regenerated fibres. ### Claim 5 (depends on 1) The haemostatic wound dressing according to claim 1, wherein the halloysite is selected from the group consisting of Halloysite-7 Å, Halloysite-10 Å. ### Claim 6 (depends on 1) The haemostatic wound dressing according to claim 1, wherein the halloysite comprises halloysite nanotubes with the following dimensions: inner diameter: 10 to 20 nm (nanometre), external diameter: 50-70 nm, and length: 0.3-4 um (micrometre). ### Claim 7 (depends on 1) The haemostatic wound dressing according to claim 1, wherein the halloysite is applied to the textile substrate with a binding agent. ### Claim 8 (depends on 2) The haemostatic wound dressing according to claim 2, wherein the composite fibres comprise between 3% and 30% algae by volume, up to 100% milk protein by volume, or a combination thereof. ### Claim 9 (depends on 2) The haemostatic wound dressing according to claim 2, wherein additional halloysite at up to 30 volume % is incorporated into or onto the composite fibres themselves. ### Claim 10 (depends on 1) The haemostatic wound dressing according to claim 1, further comprising a binding agent that comprises 90%-95% by mass of deionized water and 5%-10% by mass of acrylate or gelatin. ### Claim 11 (depends on 1) The haemostatic wound dressing according to claim 1, wherein the halloysite covers at least 30% of a surface area of the first surface of the textile substrate. ### Claim 12 (depends on 1) The haemostatic wound dressing according to claim 1, wherein the haemostatic wound dressing comprises a halloysite content of 10 g/m2-60 g/m2. ### Claim 13 (depends on 1) A method of treating an injured subject having a wound comprising: applying the haemostatic wound dressing according to claim 1 to the wound, and allowing sufficient time for the haemostatic wound dressing to treat the wound. ### Claim 14 (depends on 13) The method of claim 13 wherein the haemostatic wound dressing provides coagulation to the wound and does not cause new bleeding upon removal from the wound. ### Claim 15 (depends on 13) The method of claim 13 wherein the haemostatic wound dressing provides clot promotion to the wound. ### Claim 16 (depends on 13) The method of claim 13 wherein the haemostatic wound dressing provides biocidal effect to the wound. ### Claim 17 (depends on 13) The method of claim 13 wherein the wound is an acute wound.